<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Inhibitex Inc</title>
	<atom:link href="http://www.stockbloghub.com/tag/inhibitex-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(ILMN) Two Major Biotech Trends In 2012</title>
		<link>http://www.stockbloghub.com/2012/01/19/ilmn-two-major-biotech-trends-in-2012/90438</link>
		<comments>http://www.stockbloghub.com/2012/01/19/ilmn-two-major-biotech-trends-in-2012/90438#comments</comments>
		<pubDate>Thu, 19 Jan 2012 23:34:54 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Illumina Inc]]></category>
		<category><![CDATA[ILMN]]></category>
		<category><![CDATA[Inhibitex Inc]]></category>
		<category><![CDATA[INHX]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[Pharmasset Inc]]></category>
		<category><![CDATA[VRUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=90438</guid>
		<description><![CDATA[by Marc Lichtenfeld, Investment U Senior Analyst Wednesday, January 18, 2012: Issue #1689 The workers at the restaurants and bars around Union Square in San Francisco have likely just about caught their breath. The 10,000 or so businesspeople who descended on the neighborhood for the J.P. Morgan Healthcare Conference drank their fill of Patron, ate a few tons of filets and guzzled thousands of gallons of Starbucks coffee. What makes the conference such a big deal is that it’s the largest and most important investor event of the year in the healthcare sector. There are other healthcare conferences put on by investment banks, but nothing comes close to the quality and number of companies and attendees at JPM. There were two important takeaways that emerged from the conference – themes ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/19/ilmn-two-major-biotech-trends-in-2012/90438/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb Company Kicks Off 2012 Pharma Deals</title>
		<link>http://www.stockbloghub.com/2012/01/09/bmy-bristol-myers-squibb-company-kicks-off-2012-pharma-deals/89883</link>
		<comments>http://www.stockbloghub.com/2012/01/09/bmy-bristol-myers-squibb-company-kicks-off-2012-pharma-deals/89883#comments</comments>
		<pubDate>Mon, 09 Jan 2012 16:34:20 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Inhibitex Inc]]></category>
		<category><![CDATA[INHX]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Pharmasset Inc]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[VRUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=89883</guid>
		<description><![CDATA[The spate of acquisitions in the pharma industry continues in 2012 with Bristol-Myers Squibb Company (BMY) announcing the first major deal of the new year. Major merger and acquisition (M&#38;A) deals have taken place in the pharma sector over the last couple of years. With most of the big pharma players already facing or likely to face generic threats to their key products, the companies are resorting to M&#38;As and in-licensing deals to counter the loss of revenues that will arise following the genericization of its key drugs. Pharma major Bristol-Myers is no exception as the generic threat looms over many of its key drugs, including the blockbuster blood-thinner Plavix, co-developed with Sanofi (SNY). Bristol-Myers is looking to combat the generic threat through partnering deals and acquisitions, and is introducing ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/09/bmy-bristol-myers-squibb-company-kicks-off-2012-pharma-deals/89883/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(INHX) Inhibitex Pipeline Moves Forward &#8211; Phase II FV-100 Trial Progressing as Planned</title>
		<link>http://www.stockbloghub.com/2010/03/29/inhx-inhibitex-pipeline-moves-forward-phase-ii-fv-100-trial-progressing-as-planned/31620</link>
		<comments>http://www.stockbloghub.com/2010/03/29/inhx-inhibitex-pipeline-moves-forward-phase-ii-fv-100-trial-progressing-as-planned/31620#comments</comments>
		<pubDate>Mon, 29 Mar 2010 21:33:29 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Inhibitex Inc]]></category>
		<category><![CDATA[INHX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=31620</guid>
		<description><![CDATA[On January 11, 2010, Inhibitex (INHX) announced that the independent Data Safety Monitoring Board (DSMB) met, as scheduled, in early December 2009 to review the 30-day follow-up data on the first quartile of patients enrolled in the company’s ongoing phase II clinical trial of FV-100. Based upon its review, the DSMB unanimously recommended that the trial should continue, as originally designed, without modification. Although the data is only from the first 90 patients, we view this as good news for Inhibitex and the efficacy of FV-100 relative to Valtrex. Management anticipates that an interim analysis of the complete 30-day follow-up data on the first half (~180) of patients enrolled in the trial will be completed in the next few weeks. The interim analysis will look at the primary endpoint of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/29/inhx-inhibitex-pipeline-moves-forward-phase-ii-fv-100-trial-progressing-as-planned/31620/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(INHX) Inhibitex&#8217;s Cash Position Now Solid</title>
		<link>http://www.stockbloghub.com/2009/11/09/inhx-inhibitexs-cash-position-now-solid/20042</link>
		<comments>http://www.stockbloghub.com/2009/11/09/inhx-inhibitexs-cash-position-now-solid/20042#comments</comments>
		<pubDate>Mon, 09 Nov 2009 23:28:55 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Inhibitex Inc]]></category>
		<category><![CDATA[INHX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20042</guid>
		<description><![CDATA[On November 6, 2009, Inhibitex (INHX) reported financial results for the third quarter period ending September 30, 2009. Total revenues for the quarter were $0.29 million and consisted of $0.25 million in collaborative research and development payments and $0.04 million in licenses fees. Net loss for the third quarter totaled $4.5 million, or $0.10 per share. This was in-line with our forecast. The company exited the third quarter with $21.1 million in cash, equivalents and short-term investments. This amount does not include the approximately $23 million in gross procedures raised in late October through the private placement of common stock and warrants to new and existing shareholders. We forecast that Inhibitex will exit 2009 with approximately $37 million in cash and investments. This should be enough to fund operations Incorporatedluding completing the ongoing phase ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/09/inhx-inhibitexs-cash-position-now-solid/20042/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

